NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
AcelRx Pharmaceuticals Inc (F: R5X)
R5X Technical Analysis
5
As on 23rd Dec 2022 R5X STOCK Price closed @ 2.11 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.62 & Strong Buy for SHORT-TERM with Stoploss of 1.03 we also expect STOCK to react on Following IMPORTANT LEVELS. |
R5XSTOCK Price
Open | 2.11 | Change | Price | % |
High | 2.11 | 1 Day | 0.19 | 9.90 |
Low | 2.11 | 1 Week | 0.35 | 19.89 |
Close | 2.11 | 1 Month | 1.93 | 1072.22 |
Volume | N/A | 1 Year | 0.97 | 85.09 |
52 Week High 3.52 | 52 Week Low 0.13 |
F Germany Most Active Stocks
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
ENB | 47.60 | -0.92% |
TEF | 3.84 | -0.52% |
TEF | 3.84 | -0.52% |
WHL | 5150.00 | -0.44% |
WDI | 0.05 | -37.50% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
R5X Daily Charts |
R5X Intraday Charts |
Whats New @ Bazaartrend |
R5X Free Analysis |
|
R5X Important Levels Intraday
RESISTANCE | 2.11 |
RESISTANCE | 2.11 |
RESISTANCE | 2.11 |
RESISTANCE | 2.11 |
RESISTANCE | 2.11 |
RESISTANCE | 2.11 |
RESISTANCE | 2.11 |
RESISTANCE | 2.11 |
R5X Forecast April 2025
4th UP Forecast | 2.67 |
3rd UP Forecast | 2.49 |
2nd UP Forecast | 2.38 |
1st UP Forecast | 2.27 |
1st DOWN Forecast | 1.95 |
2nd DOWN Forecast | 1.84 |
3rd DOWN Forecast | 1.73 |
4th DOWN Forecast | 1.55 |
R5X Weekly Forecast
4th UP Forecast | 2.53 |
3rd UP Forecast | 2.40 |
2nd UP Forecast | 2.31 |
1st UP Forecast | 2.23 |
1st DOWN Forecast | 1.99 |
2nd DOWN Forecast | 1.91 |
3rd DOWN Forecast | 1.82 |
4th DOWN Forecast | 1.69 |
R5X Forecast2025
4th UP Forecast | 8.64 |
3rd UP Forecast | 6.55 |
2nd UP Forecast | 5.25 |
1st UP Forecast | 3.96 |
1st DOWN Forecast | 0.26 |
2nd DOWN Forecast | -1.03 |
3rd DOWN Forecast | -2.33 |
4th DOWN Forecast | -4.42 |
AcelRx Pharmaceuticals Inc ( F Germany Symbol : R5X )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
R5X Other Details
Segment | EQ | |
Market Capital | 95718376.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
R5X Address
![]() |
R5X Latest News
R5X Business Profile
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is based in Hayward, California. Address: 25821 Industrial Boulevard, Hayward, CA, United States, 94545
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service